Management of Retinitis Pigmentosa Via Wharton’s Jelly-Derived Mesenchymal Stem Cells or Combination with Magnovision: Three-Year Prospective Results

Researchers investigated whether the natural progression rate of retinitis pigmentosa could be decreased with subtenon Wharton’s jelly-derived MSC application alone, or combination with Magnovision.
[Stem Cells Translational Medicine]
Full ArticleGraphical Abstract

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News